GD3 mediated immune response via vascular endothelial growth factor in ovarian cancer

Cancer constitutes a major public health problem and one of the most frequent causes of death in the Western world. It has been reported that 1,685,210 new cancer cases and 595,690 deaths from cancer are estimated to occur in the United States in 2016 (1). The economic burden of cancer is associated with expenditures including aspects such as prevention, screening and treatment services and the lost productivity due to cancer-related death (2). Furthermore it has been estimated that by 2030, the number of new cases in various types of the disease will reach 23 million per year corresponding to an increase of 70% when compared to relevant data from 2012 (3).